INAB Insider Trading

Insider Ownership Percentage: 35.80%
Insider Buying (Last 12 Months): $1,565,995.20
Insider Selling (Last 12 Months): $0.00

IN8bio Insider Trading History Chart

This chart shows the insider buying and selling history at IN8bio by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

IN8bio Share Price & Price History

Current Price: $2.31
Price Change: Price Decrease of -0.07 (-2.94%)
As of 12/7/2022 11:06 AM ET

This chart shows the closing price history over time for INAB up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
Want To Catch The Next Hot Investing Trend (Look Inside?)
While millennials are trying to get rich in crypto Ponzi schemes- there's something happening that Wall Street is TOTALLY ignoring. And it's about to affect every American Citizen over 55...
And It Could Spark An Economic Boom For Investors

IN8bio Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/16/2022Emily FairbairnDirectorBuy789,473$1.90$1,499,998.704,111,958View SEC Filing Icon  
8/16/2022Kate RochlinCOOBuy5,263$1.90$9,999.705,263View SEC Filing Icon  
8/16/2022Lawrence LambEVPBuy526$1.90$999.4099,730View SEC Filing Icon  
8/16/2022Trishna GoswamiInsiderBuy2,631$1.90$4,998.902,631View SEC Filing Icon  
8/16/2022William Tai-Wei HoCEOBuy26,315$1.90$49,998.502,315,745View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for IN8bio (NASDAQ:INAB)

12.98% of IN8bio stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at INAB by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

IN8bio Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
11/15/2022Vanguard Group Inc.169,528$0.34M0.0%+53.1%0.692%Search for SEC Filing on Google Icon
11/15/2022Precept Management LLC50,000$0.10M0.7%N/A0.204%Search for SEC Filing on Google Icon
11/7/2022Warberg Asset Management LLC15,000$30K0.0%N/A0.080%Search for SEC Filing on Google Icon
11/2/2022Voss Capital LLC375,570$0.76M0.2%-25.7%1.993%Search for SEC Filing on Google Icon
10/28/2022Stonegate Investment Group LLC232,310$0.47M0.0%-12.8%1.233%Search for SEC Filing on Google Icon
10/24/2022United Asset Strategies Inc.14,000$28K0.0%N/A0.074%Search for SEC Filing on Google Icon
8/15/2022Nantahala Capital Management LLC148,801$0.36M0.0%-57.8%0.790%Search for SEC Filing on Google Icon
8/13/2022Voss Capital LLC505,635$1.14M0.4%+95.2%2.684%Search for SEC Filing on Google Icon
8/9/2022Stonegate Investment Group LLC266,500$0.60M0.0%N/A1.415%Search for SEC Filing on Google Icon
5/13/2022Nantahala Capital Management LLC352,753$1.23M0.1%-5.5%1.875%Search for SEC Filing on Google Icon
5/13/2022Vanguard Group Inc.111,493$0.37M0.0%-7.3%0.593%Search for SEC Filing on Google Icon
5/12/2022BlackRock Inc.16,334$54K0.0%+70.8%0.087%Search for SEC Filing on Google Icon
5/11/2022Rock Creek Group LP86,032$0.30M0.0%+87.5%0.457%Search for SEC Filing on Google Icon
4/20/2022Sigma Planning Corp97,750$0.33M0.0%+241.8%0.520%Search for SEC Filing on Google Icon
2/11/2022Ensign Peak Advisors Inc70,028$0.31M0.0%N/A0.373%Search for SEC Filing on Google Icon
2/10/2022HighTower Advisors LLC10,000$44K0.0%N/A0.053%Search for SEC Filing on Google Icon
2/2/2022Sigma Planning Corp28,600$0.13M0.0%N/A0.153%Search for SEC Filing on Google Icon
11/16/2021Voss Capital LLC80,727$0.56M0.2%N/A0.430%Search for SEC Filing on Google Icon
11/16/2021Capital World Investors800,000$5.52M0.0%N/A4.266%Search for SEC Filing on Google Icon
11/15/2021Tudor Investment Corp Et Al63,287$0.43M0.0%N/A0.337%Search for SEC Filing on Google Icon
11/10/2021B. Riley Financial Inc.257,378$1.76M0.2%N/A1.372%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
IN8bio logo
IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidate includes INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation. It also develops INB-400 and INB-300 that is in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.
Read More on IN8bio

Today's Range

Now: $2.31
Low: $2.31
High: $2.31

50 Day Range

MA: $1.80
Low: $1.39
High: $2.44

52 Week Range

Now: $2.31
Low: $1.38
High: $7.25

Volume

300 shs

Average Volume

52,529 shs

Market Capitalization

$56.60 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.47

Who are the company insiders with the largest holdings of IN8bio?

IN8bio's top insider shareholders include:
  1. Emily Fairbairn (Director)
  2. William Tai-Wei Ho (CEO)
  3. Lawrence Lamb (EVP)
  4. Kate Rochlin (COO)
  5. Trishna Goswami (Insider)
Learn More about top insider investors at IN8bio.

Who are the major institutional investors of IN8bio?

IN8bio's top institutional investors include:
  1. Voss Capital LLC — 1.99%
  2. Stonegate Investment Group LLC — 1.23%
  3. Vanguard Group Inc. — 0.69%
  4. Precept Management LLC — 0.20%
  5. Warberg Asset Management LLC — 0.08%
  6. United Asset Strategies Inc. — 0.07%
Learn More about top institutional investors of IN8bio stock.

Which institutional investors are selling IN8bio stock?

Within the last quarter, INAB stock was sold by these institutional investors:
  1. Voss Capital LLC
  2. Stonegate Investment Group LLC

Which institutional investors are buying IN8bio stock?

In the last quarter, INAB stock was bought by institutional investors including:
  1. Vanguard Group Inc.
  2. Precept Management LLC
  3. Warberg Asset Management LLC
  4. United Asset Strategies Inc.
During the last year, these company insiders have bought IN8bio stock:
  1. Emily Fairbairn (Director)
  2. William Tai-Wei Ho (CEO)
  3. Lawrence Lamb (EVP)
  4. Kate Rochlin (COO)
  5. Trishna Goswami (Insider)
Learn More investors buying IN8bio stock.
Want To Catch The Next Hot Investing Trend (Look Inside?)
While millennials are trying to get rich in crypto Ponzi schemes- there's something happening that Wall Street is TOTALLY ignoring. And it's about to affect every American Citizen over 55...
And It Could Spark An Economic Boom For Investors